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Abstract
Background: To investigate the interchangeability of measures of disability and health-related
quality of life (HRQL) by comparing their associations patterns with disease-related impairment
measures in patients with a variety of conditions.
Methods: A systematic literature search of MEDLINE, EMBASE, Web of Science and a hand search
of reference lists through January 2006. Studies were included if they reported associations
patterns between impairment and disability and between impairment and HRQL. Correlation
coefficients were transformed to Fisher's z effect size (ES(z)). Weighted averages were reported
as pooled ES(z) with 95% confidence intervals (CI).
Results: The relationship between impairment and disability was stronger (pooled ES(z) = 0.69;
95% CI, 0.66 – 0.72) than between impairment and HRQL (pooled ES(z) = 0.38; 95% CI, 0.36 –
0.41). The physical component score (pooled ES(z) = 0.43; 95% CI, 0.39 – 0.47) and disease-specific
HRQL (pooled ES(z) = 0.46; 95% CI, 0.40 – 0.51) were stronger associated with impairments than
the mental component score (pooled ES(z) = 0.28; 95% CI, 0.20 – 0.36) and generic HRQL (pooled
ES(z) = 0.36; 95% CI, 0.33 – 0.39).
Conclusion: This study shows measures of disability and different HRQL domains were not
equally related to impairment. Patient's impairments are better reflected in disability measures,
than in HRQL instruments. There are many outcomes of interest and precisely defining them and
measuring them will improve assessing the impact of new interventions.
Background
Choosing an outcome measure for use in clinical research
is a complex process. If the outcomes are chosen inappro-
priately, a study may provide unreliable results [1]. Fre-
quently used outcomes measures are mortality rates,
number of events (recurrent myocard infarction) or dis-
ease activity (lesion load on MRI).
Besides biological measures other levels of clinical meas-
urement can be considered in clinical studies: impair-
ments, disability and health-related quality of life
(HRQL). Impairments are the direct organic manifesta-
tions of the disease such as consciousness and paresis
[2,3]. Disability can be defined as limitations in carrying
out activities of daily living, such as self-care, mobility and
activities inside or outside the home [2,3]. HRQL refers to
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a broad spectrum of consequences of disease. Although
this concept also includes elements of impairments and
disabilities, it has a strong focus on patient's social func-
tioning and perceived health status and well being [4,5].
Hence, impairment measures are closely related to the
patient's disorder, whereas the other outcome measures
focus on the patient's level of functional health. Each sub-
sequent level of clinical measurement is increasingly less
disease-specific and more relevant to the patient.
Recently, patient-relevant outcomes in terms of disability
and HRQL have become more important [6]. Although
both functional outcomes reflect the consequences of dis-
eases on personal level, they are conceptually different
and not synonymous as is often thought by clinical
researchers. Consequently, the decision to use one of
these measures can have important implications for the
interpretation of the study results. The objective of this
systematic review is to investigate the interchangeability
of measures of disability and HRQL by comparing their
association patterns with disease-related impairment
measures.
Methods
Data sources
We conducted a systematic literature search of MEDLINE
from 1966 through January 2006, EMBASE from 1980
through January 2006 and Web of Science from 1988
through January 2006 to identify studies addressing the
relation between outcome measures. A search strategy
using Medical Subject Heading, text words and Publica-
tion Types Impairment or Body function (Publication date
from 2001) or Body structure (Publication date from 2001)
and Disability (Evaluation) or Activity or Disabled Persons or
Activities of Daily Living and Health-related quality of life
combined with Association or Evaluation Studies or Compar-
ative Study or Validation Studies was used. Studies from
English, German and French literature were included. The
electronic search was supplemented by hand searching
the investigators files, and retrieval of references cited in
available literature. The search strategy was composed by
one of the authors (NW) in consultation with a clinical
librarian.
Study selection
A set of explicit criteria, composed by three investigators
(NW, RdH, MV), were used for selection of the literature.
Articles were included if they focused on methodological
or metric aspects of patient-based outcomes (for example,
methods of evaluating such measures, psychometric or
clinimetric assessment of measures, comparative studies
of measures).
Studies were included in which both the association
between impairment and disability, and between impair-
ment and HRQL were calculated by means of correlation
coefficients or other association measures, regardless of
the disease with the exception of psychiatric disorders.
Hence, to improve the comparability between the correla-
tion patterns between the different health concepts, only
studies were included in which the three types of health
outcomes were assessed in the same patient population.
The measurement instruments were questionnaires or
observation lists. When a multi-scale questionnaire
focuses on more than one concept we only included the
sub-scale for the health domain in question. In case of
double publication we selected the first publication in
time. Excluded were studies which valuated HRQL in
terms of utilities [7] or composite scores of conceptual dif-
ferent measures.
Data extraction
All data were independently abstracted by two investiga-
tors (NW, RdH) through use of a list of the criteria com-
posed by three investigators. After study selection,
measures were categorized according the definitions of
the WHO International Classification of Impairments, Disa-
bilities, and Handicap version [2] and the revised Interna-
tional Classification of Functioning [3]. Outcome measures
were classified into one of the following categories:
impairment, disability, and HRQL. The latter was further
categorized into generic HRQL, disease-specific HRQL,
mental component of HRQL and physical component of
HRQL. When there was doubt on the classification of the
health domain a third reviewer (MV) was consulted.
A first draft synthesizing the data was produced by the first
author of this review (NW) and extensively criticized by
two other authors. The following information was
abstracted: author, year of publication, sample size, dis-
ease, type of impairment and disability scales, distinction
between generic or disease-specific and mental or physical
HRQL, and the associations with impairment. Studies
reporting repeated measures only baseline data was
abstracted. Disagreements in abstracting were solved by
discussion.
Statistical analysis
The correlations coefficients (r) published were converted
using Fischer's variance stabilizing z transform (ES(z)) [8].
ES(z) = 1/2 loge [1+r/1-r]
were the asymptotic variance was:
v ES(z) = 1/n-3
Mean ES(z) were calculated for studies reporting multiple
correlations between the concepts studied [9]. The ES(z)
were combined using a fixed or random effects model,BMC Medical Research Methodology 2007, 7:24 http://www.biomedcentral.com/1471-2288/7/24
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when appropriate. The weight for each study was inversely
proportional to the square root of the number of patients
included in the study. The methods for obtaining the
pooled ES(z) and its 95% confidence interval (CI) are
described in detail elsewhere [10]. We labeled the strength
of the ES 0.20 as small, 0.50 as medium and 0.80 as large
[11]. The pooled ES(z) were converted back to a correla-
tion coefficient [12]:
r = tanh(ES(z))
in which we labeled the strength of the association; abso-
lute values of r, 0.00–0.19 is regarded as very weak, 0.20–
0.39 as weak, 0.40–0.59 as moderate, 0.60–0.79 as strong
and 0.80–1.00 as very strong correlation [13]. The back-
ward transformed correlation coefficients were also
expressed in variance explained (r2). The square of the cor-
relation coefficient tells us what proportion of the vari-
ance of one variable can be explained by the linear
correlation with the other.
Statistical heterogeneity was measured using the
Cochrane Q statistics; p ≤ 0.10 was considered representa-
tive of significant statistical heterogeneity. To establish the
effect of heterogeneity between studies on meta-analysis
conclusions, we performed several subgroup analyses:
impairment in relation to generic or disease-specific
HRQL and impairment versus the physical or mental
aspects of HRQL.
We constructed normal quantile plots to assess whether
the ES(z) estimates are (approximately) normal distrib-
uted and to search for publication bias [14]. With regard
to the presence of publication bias we also used the Spear-
man's rho rank correlation method [12] to test the rela-
tionship between the standardized ES(z) and sample size
(p < 0.05 indicates significant publication bias) and a fail-
safe number approach. A fail-safe number is the number
of non-significant, unpublished, or missing studies that
would need to be added to the meta-analysis in order to
change the results of the analysis. If this number is relative
large to the number of observed studies, the observed
results, even with some publication bias, can be treated as
a reliable estimate of the true effect [15]. All analyses were
performed in Meta-Win, version 2.0.
Results
Study characteristics
Our initial search yielded 434 potentially literature cita-
tions (Figure 1). Of these, 125 were excluded based on
title (70 were investigating a psychiatric disorder, 44 were
review articles, nine articles measured caregiver burden,
one article reported data about a composite score and one
reported HRQL in terms of utilities). Abstracts from 309
articles were retrieved and additional 188 articles were
excluded (134 studies did not measure all three health
domains, 49 did not report concrete associations between
the health domains, three were investigating a psychiatric
disorder, one reported data about a composite score and
one reported HRQL in terms of utilities), leaving 121 arti-
cles for full review. Of these, 90 were excluded (44 did not
report association patterns, 34 articles measured not all
three domains, in five articles impairment measures were
no scale score, four articles used composite scores, one
reported utility based HRQL, one concerned a proxy
measure and one a double publication).
A total of 31 studies, with an average sample size of 401
(range 38 – 6497) persons, were found to conform to our
inclusion criteria [16-46] (Table 1). Seven studies
reported data on outcome measures in patients with
arthritis, six on Multiple Sclerosis, three on Parkinson's
disease, two on stroke, two on spinal cord injury, four on
a variety of joint diseases (knee, patella, elbow, shoulder),
one cervical dystonia, one diabetic neuropathy, one facial
nerve paralysis, one AIDS, one chronic dysphonia, one
chronic obstructive pulmonary disease, and one on pso-
riasis.
The studies included a wide range of disease-related
impairment measures, as well as a variety of disability
measures (Table 1), in which the Functional Independ-
ence Measure (FIM) was the most often used. With regard
to the HRQL measures, 17 studies used the SF-36 (or SF-
20), 12 studies reported both the physical component and
mental component scores, in two studies [37,42] the
mental health dimension was considered as mental
HRQL. Other scales that were considered as a mental com-
ponent of HRQL were the psychosocial dimension of the
Sickness Impact Profile (SIP) [21,22,34], psychological
well-being and the General Health Questionnaire (GHQ)
[26], the mental dimension of the Multiple Sclerosis
HRQL scale (MSQL) [36], the social well-being dimen-
sion of the Facial Disability Index (FDI) [28], the Overall
Rating of Life satisfaction (ORLS) [20], and the emotional
subscale of the Voice Handicap Index (VHI) [43].
Overall the studies included 86 correlations between
impairment and disability and 104 correlations between
impairment and HRQL. Five studies reported only one
single correlation [24,25,28,33,44], for the remaining
studies mean ES(z) were calculated for each health
domain. Table 2 presents effect sizes of the 31 studies
included. Thirteen studies (42%) reported large ES(z)
between impairment and disability (≥ 0.81), whereas
81% of the ES(z) related to HRQL was small to moderate
(≤ 0.50). The ES(z) between impairment and the different
types of HRQL were on average small to moderate, except
for disease-specific HRQL; 50% of the studies reported
moderate to large ES(z) (0.51 – 0.80).BMC Medical Research Methodology 2007, 7:24 http://www.biomedcentral.com/1471-2288/7/24
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Data synthesis
Review of the normal quantile plots (Figure 2 and 3)
showed that one study [46] substantially deviated from
normality. Removal of this study revealed statistical
homogeneity of the datasets for the association between
impairment and disability (Q statistics, p = 0.34), and
between impairment and HRQL (Q statistics, p = 0.15).
On aggregate level (Figure 4), there was a moderate to
large association between impairment and disability
(pooled ES(z) = 0.69; 95% CI, 0.66 – 0.72). The aggre-
gated relationship between impairment and HRQL was
statistically significant smaller (pooled ES(z) = 0.38; 95%
CI, 0.36 – 0.41). Backward transformation in correlation
coefficients resulted in a moderate association between
impairment and disability (r = 0.60; r2 = 36%) and a weak
association between impairment and HRQL (r = 0.36; r2 =
13%).
Subgroup analyses
Table 2 presents the ES(z) per study used for the subgroup
analyses. Figure 4 also depicts the various impairment –
HRQL subgroup analyses. No statistical heterogeneity
could be demonstrated (range p-values of the Q statistics
0.35 – 0.44), with the exception of the association
between impairment and the mental component of
HRQL (p = 0.06).
The pooled ES(z) between impairment and generic HRQL
measures was 0.36 (95% CI, 0.33 – 0.39; r = 0.35; r2 =
12%) [16-22,24-27,29-32,34,37-42,45]. The pooled ES(z)
between impairment and disease-specific HRQL measures
was significantly higher (pooled ES(z) = 0.46; 95% CI,
0.40 – 0.51; r = 0.43; r2  = 18%)
[23,28,29,33,35,36,40,43,44,46]. Impairment measures
were significantly higher related with the physical compo-
nent of the HRQL measures (pooled ES(z) = 0.43; 95% CI,
0.39 – 0.47; r = 0.41; r2  = 17%)
[16,17,19,26,27,31,32,34,36,38-40,45] than with the
mental component (pooled ES(z) = 0.28; 95% CI, 0.20 –
0.36 [random effects model]; r = 0.27; r2 = 7%) [16,17,19-
22,26-29,31,32,34,36-40,42,43,45].
Publication bias
Review of normal quantile plots showed no clear indica-
tions for publication bias in both the analyses for the rela-
tionship impairment and disability and for impairment
and HRQL (Figure 2 and 3). In addition, publication bias
was not evident when the Spearman's rho rank correlation
method was used (both p > 0.50). The fail-safe calculation
by Rosenthal's method retrieved for both analyses a large
number of studies (n = 27077/n = 9755) needed to be
added in order to change the results of the meta-analysis.
Discussion
In this study we investigated the impact of impairments
on patients' functional health in a spectrum of diseases.
The results of the meta-analysis show that impairments
explain 36% of the variance of the disability scores and
13% of the variance of HRQL scores. Impairment scales
account for 17% of the physical dimension of HRQL, but
can explain no more than 7% of the psychological aspects
of HRQL [47].
Due to the great variability in disease-related impairment
scales and disability and HRQL instruments used in
patient groups with a wide range of disorders, we expected
heterogeneous data sets. Interestingly, after removal of
Summary description of the studies included and excluded in  the meta-analysis Figure 1
Summary description of the studies included and excluded in 
the meta-analysis.
434 Citations identified and screened
125 excluded
70 psychiatric disorders
44 reviews
  9 caregiver burden
  1 composite score
  1 utility
309 Abstracts retrieved for detailed
evalution
188 excluded
134 not all three health domains
  49 no association
    3 psychiatric disorders
    1 composite score
    1 utility
121 full text articles retrieved for detailed
information
90 excluded
44 no association
34 not all three health domains
5 no scale scores
4 composite scores
1 utility
1 proxy
1 double publication
31 articles includedB
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Table 1: Information on the 31 studies included in the analysis ordered on disease
References N Disease Impairment Disability HRQL
Generic Specific
Deyo, 1983 [22] 97 Arthritis Morning stiffness Grip strength SIP physical ARA SIP total SIP psychosocial
Birrell, 1998 [19] 86 Arthritis OSRA HAQ SF-36
Kvien, 1998 [29] 1030 Arthritis VAS pain VAS fatigue MHAQ SF-36 AIMS2
Wolfe, 2000 [45] 1773 Arthritis Global GI severity HAQ SF-36
Angst, 2004 [16] 43 Arthritis cASES pASES DASH SF-36
Angst, 2005 [17] 79 Arthritis cASES pASES DASH SF-36
Salaffi, 2005 [39] 244 Arthritis WOMAC-Pain WOMAC-Stiffness WOMAC-Function SF-36
Rothwell, 1997 [37] 42 Multiple sclerosis EDSS OPCS SF-36
Sharrack, 1999 [42] 50 Multiple sclerosis EDSS SNRS Barthel Index FIM CAMBS dis. AI SF-36 EuroQol VAS
Schwartz, 1999 [41] 274 Multiple sclerosis SI Disease steps AI HSQ
Miller, 2000 [34] 300 Multiple sclerosis EDSS MSFC SIP physical SIP psychosocial SF-36
Hobart, 2000 [26] 64 Multiple sclerosis EDSS Barthel Index FIM SF-36 Well-being GHQ
Rasova, 2005 [36] 112 Multiple sclerosis Muscle performance Pulmonary ventilation Barthel Index MSQL
Rubenstein, 1998 [38] 193 Parkinson's disease HY UPDRS motor FSQ (BADL, IADL) SF-36
Schrag, 2000 [40] 79 Parkinson's Disease H&Y UPDRS motor PDQ-39 ADL EuroQol VAS SF-36 PDQ-39
Franchignoni, 2005 [23] 70 Parkinson's Disease BBS PCS UPDRS-ADL PDQ-39
de Haan, 1993 [21] 81 Stroke Mathew Orgogozo SSS NIHSS CNS Barthel Index SIP
Gottlieb, 2001 [25] 100 Stroke Clas. Reding FIM LSI-a
Fuhrer, 1992 [24] 140 Spinal Cord Injury ASIA FIM LSI-a
May, 2002 [33] 98 Spinal Cord Injury ASIA FIM QLI
Marx, 2001 [32] 42 Knee disorders AAOS Lysholm scale KOS-ADL SF-36
Paxton, 2003 [35] 110 Patellar dislocation Fulkerson Kujala IKDC Lysholm Tegner MFA
MacDermid, 2001 [31] 70 Elbow pathology ASES pain PREE pain DASH SF-36
Beaton, 1996 [18] 90 Shoulder disorder Elevation of the shoulder SST pASES SF-36 (acute version)
Lindeboom, 1998 [30] 64 Cervical dystonia Tsui TWSTRS-P TWSTRS-D SF-20
Vinik, 2005 [44] 262 Diabetic neuropathy TNS QOL-DN ADL QOL-DN
Kahn, 2001 [28] 86 Facial nerve paralysis FaCE FDI – physical functioning FDI – 
social-well 
being
Cleary, 1993 [20] 189 AIDS Extreme pain Total symptom score FSQ (BADL, IADL) ORLS Mental Health
Speyer, 2004 [43] 77 Chronic dysphonia Voice disorder severity Impairment daily living VHI
Hu, 2005 [27] 58 COPD Breathlessness (VAS) BDI PSFDQ-Act SF-36
Zachariae, 2002 [46] 6497 Psoriasis PASI Severity PDI PLSI
Abbreviations (in alphabetic order):
AAOS: American Academy of Orthopaedic Surgeons sports knee-rating scale. AI: Ambulation Index. AIMS2: Arthritis Impact Measurement Scales revised. ARA: American Rheumatism Association's functional 
classes. ASIA: Total Motor Index Score. (p)cASES: (patient) clinical American Shoulder and Elbow Surgeons questionnaire. BBS: Berg Balance Scale. BDI: Baseline Dyspnea Index. CAMBS: Cambridge Multiple 
Sclerosis Basic Score. CNS: Canadian Neurological Scale. COPD: Chronic Obstructive Pulmonary Disease. DASH: Disability of the Arm, Shoulder and Hand questionnaire. EDSS: Kurtzke Expanded Disability 
Scale. FaCE: Facial Clinimetric Evaluation. FDI: Facial Disability Index. FIM: Functional Independence Measure. FSQ: Functional Status Questionnaire (BADL: basic activities of daily life, IADL: instrumental 
activities of daily life). GHQ: General Health Questionnaire. Global GI severity: global gastrointestinal severity. HAQ: Stanford Health Assessment Questionnaire functional disability index. HSQ: Health Status 
Questionnaire. H&Y: Hoehn and Yahr. IKDC: International Knee Documentation Committee form. KOS: Knee Outcome Scale. LSIa: Life Satisfaction Index, version A. MFA: Musculoskeletal Function 
Assessment. MHAQ: Modified Health Assessment Questionnaire. MSFC: Multiple Sclerosis Functional Composite. MSQL: Multiple Sclerosis Quality of life scale. NIHSS: National Institutes of Health Stroke 
Scale. OPCS: Office of Population Census and Survey disability scale. ORLS: Overall Rating of Life Satisfaction. OSRA: Overall Status measure for Rheumatoid Arthritis. PASI: Psoriasis Area and Severity Index. 
PCS: Postural Changes Scale. PDI: Psoriasis Disability Index. PDQ-39: Parkinson Disease Questionnaire. PFSDQ-Act: Pulmonary Functional Status and Dyspnea Questionnaire. PLSI: Psoriasis Life Stress 
Inventory. PREE: Patient-rated Elbow Evaluation. QLI: Ferrans and Powers Quality of life Index. QOL-DN: Norfolk Quality of life Questionnaire-Diabetic Neuropathy. SF-20: Medical Outcome Study 20-Item 
Short-Form Health Survey. SF-36: Medical Outcome Study 36-Item. SI: Symptom Inventory. SNRS: Scripps Neurological Rating Scale. SSS: Scandinavian Stroke Scale. SST: Simple Shoulder Test. TNS: Total 
Neuropathy Score. TWSTRS-P(D): Toronto Western Spasmodic Torticollis Rating Scale-Pain(Disability). UPDRS: Unified Parkinson' Disease Rating Scale. VHI: Voice Handicap Index. WOMAC; Western 
Ontario and McMaster Universities.BMC Medical Research Methodology 2007, 7:24 http://www.biomedcentral.com/1471-2288/7/24
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one study which deviated from normality, homogeneity
could be demonstrated in all analyses, except when we
investigated the relationship between impairment and the
mental component of HRQL. Possibly, this type of HRQL
is less clearly defined compared to the other types of func-
tional outcomes.
Treatments, such as new drugs or new surgical or radiolog-
ical interventions, are aimed at reducing mortality and
morbidity. If these treatments reduce impairments, the
beneficial effects on functional health will be far more
better detectable in the patient's level of disability than in
his or her level of HRQL. Moreover, if the outcome is
assessed in terms of HRQL, treatment effects will be more
visible in the physical component than in the mental
components, and will be better reflected in the disease-
specific measures than in the generic HRQL measures.
Therefore, outcome measures at the level of functioning of
patients should be selected carefully when clinical studies
are designed. It clearly does matter on which level the
functional outcome measurement is chosen.
No doubt, HRQL scales represent an important measure
from a patient's point of view, but have serious disadvan-
tages in many clinical efficacy studies. The extent to which
patients fulfill social roles and participate in their environ-
ment cannot be observed directly and depends not only
on their functional ability, but also on personal traits,
social circumstances and societal barriers. In particular,
HRQL scores, which reflect the patient's perception of the
consequences of disease, depend on numerous addi-
tional, usually psychosocial, factors other than the disease
itself. This explains why the correlation between impair-
ments and HRQL scores is weak, especially when empha-
sis is laid on subjective psychological scores of these
scales. The subjective HRQL scores therefore are often
beyond the influence of the physician. In the primary
assessment of new drugs or new surgical procedures, there
Table 2: ES(z) of the studies included in the meta-analysis
ES(z) impairment – disability 
(n = 31)
ES(z) impairment – HRQL (n = 31)
References generic (n = 23) disease-specific 
(n = 10)
physical (n = 13) mental (n = 21)
Deyo, 1983 [22] 0.23 0.31 0.32
Birrell, 1998 [19] 0.81 0.49 0.65 0.37
Kvien, 1998 [29] 0.50 0.39 0.42 0.41
Wolfe, 2000 [45] 0.35 0.38 0.47 0.29
Angst, 2004 [16] 0.60 0.07 0.29 -0.15
Angst, 2005 [17] 0.60 0.11 0.41 -0.17
Salaffi, 2005 [39] 1.00 0.46 0.41 0.51
Rothwell, 1997 [37] 1.30 0.15 0.05
Sharrack, 1999 [42] 1.05 0.48 0.21
Schwartz, 1999 [41] 0.50 0.68
Miller, 2000 [34] 1.02 0.18 0.18 0.18
Hobart, 2000 [26] 1.33 0.06 0.34 0.14
Rasova, 2005 [36] 0.56 0.22 0.39 0.04
Rubenstein, 1998 [38] 0.73 0.40 0.48 0.31
Schrag, 2000 [40] 0.66 0.32 0.55 0.49 0.21
Franchignoni, 2005 [23] 0.79 0.71
de Haan, 1993 [21] 0.87 0.52 0.37
Gottlieb, 2001 [25] 0.55 0.16
Fuhrer, 1992 [24] 0.85 0.04
May, 2002 [33] 1.26 0.06
Marx, 2001 [32] 1.19 0.35 0.83 0.01
Paxton, 2003 [35] 0.35 0.49
MacDermid, 2001 [31] 0.85 0.41 0.54 0.29
Beaton, 1996 [18] 0.40 0.28
Lindeboom, 1998 [30] 0.23 0.21
Vinik, 2005 [44] 0.66 0.59
Kahn, 2001 [28] 0.87 0.78 0.78
Cleary, 1993 [20] 0.60 0.38 0.38
Speyer, 2004 [43] 1.05 0.55 0.44
Hu, 2005 [27] 0.46 0.45 0.29 0.60
Zachariae, 2002 [46] 0.44 0.40BMC Medical Research Methodology 2007, 7:24 http://www.biomedcentral.com/1471-2288/7/24
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are many outcomes of interest and precisely defining
them and measuring them will improve assessing the
impact of new interventions. In contrast, disability
(mobility, self-care) seem to be a more appropriate pri-
mary end point for assessing the functional health status
of patients. The ability to perform basic and complex
activities of daily life is, as we showed, not only better
related to the disease process itself, but is also observable
and predictive of dependence [48], and forms an essential
aspect of the patient's HRQL [49], an aspect which is ame-
nable for treatment.
A shortcoming of this meta-analysis might be that there
are probably more studies than the 31 we found. Our
search strategy was based on the ICIDH and ICF terms and
few researchers distinguish between the terms impair-
ment, disability and HRQL. If they distinguished between
these terms correlations between impairment and disabil-
ity or between impairment and HRQL were given rarely
for all three domains together. Another point of discus-
sion may be the concern for publication bias. However,
the normal quantile plots, Spearman's rank correlation
coefficient method and fail-safe calculation method do
not give an indication for this type of bias. Finally and
unfortunately, we were not able to perform subgroup
analysis based on the methodological quality of the stud-
ies. This because the psychometric and clinimetric articles
analyzed used a hotchpotch of research designs which
made it impossible to formulate unequivocal methodo-
logical criteria in terms of, for example, appropriateness of
Normal quantile plot for the ES(z) between impairment and disability Figure 2
Normal quantile plot for the ES(z) between impairment and disability. The plot compares two distributions by plot-
ting there quantiles against each other. One of the distributions is the standard normal distribution (X as) while the other is the 
distribution one wishes to compare it against (here the Y as is defined as ES(z)i/√i). The deviations from linearity indicate devi-
ations in normality. Publication bias will tend to leave strange gaps in the plot or lead to strange curves.BMC Medical Research Methodology 2007, 7:24 http://www.biomedcentral.com/1471-2288/7/24
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the design chosen, sample size consideration, blind
assessment of outcome parameters, statistical adjustment
for confounders, or loss to follow-up [50].
Conclusion
New drugs or new surgical or radiological treatments are
developed from a pathophysiologic perspective and are
primarily directed at reducing impairments. Traditionally,
biological and impairment measures are preferred.
Increasingly, it becomes evident that this type of outcome
is not always relevant for patients [21,51]. Our study
shows that patient's impairments are clearly better
reflected in disability measures, than in HRQL instru-
ments. The relatively low association between impair-
ment and HRQL is found in patients with various
disorders, therefore we conclude that to assess the efficacy
of a new treatment, disability is an important functional
endpoint in clinical studies.
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Normal quantile plot for the ES(z) between impairment and health-related quality of life Figure 3
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